Ribavirin monotherapy increases sustained response rate in relapsers of end treatment virologic responders

Table 2 Demography of patients with sustained virologic response after ribavirin monotherapy.

Gender, age (yr)	Genotype (b)	HCV-RNA	ALT elevation (mo)	Monotherapy (mo)	Cirrhosis
F53 (Meq/mL)	1	3.81	2	3	+
F43 (Meq/mL)	2	0.061	1	1	–
F491 (Meq/mL)	1	0.011	2	1	–
F57 (copies/mL)	2	<100	1	2	–
F50 (copies/mL)	1	<100	2	1	–
M50 (copies/mL)	1	<100	1	2	–
M58 (copies/mL)	1	<100	5	2	–

Note: ALT elevation denotes the onset of ALT ≥1.5× normal upper limit after combination therapy in months. Monotherapy denotes the onset of ribavirin monotherapy after biochemical relapse in months. ¹Non-responder at the cessation of combination therapy.